专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4420665A1 DETOXIFYING AGENT, DETOXIFYING AGENT KIT, AND NOVEL INCLUSION COMPLEX 审中-实审
公开(公告)号：EP4420665A1
公开(公告)日：2024-08-28
申请号：EP22883497.4
申请日：2022-10-14
申请人： The Doshisha
发明人： KITAGISHI, Hiroaki , MO, Saietsu
IPC分类号： A61K31/555 , A61K31/409 , A61K31/724 , A61K47/69 , A61P39/02
CPC分类号： A61K31/555 , A61P39/02 , A61K31/724 , A61K47/69 , A61K31/409
摘要： Provided are a detoxifying agent and detoxifying agent kit for simultaneous detoxification of CO and HCN in the body. The detoxifying agent for removal of carbon monoxide and hydrogen cyanide in the body includes as active ingredients a first inclusion complex wherein a first cyclodextrin dimer represented by general formula (1) below clathrates a first water-soluble metal porphyrin in which the central metal is divalent, and a second inclusion complex wherein a second cyclodextrin dimer represented by general formula (2) below clathrates the first water-soluble metal porphyrin in which the central metal is divalent, and further includes a reducing agent if necessary.

2. 发明公开

EP3156424A1 COMPOUND CONTAINING SELF-IMMOLATIVE GROUP 审中-实审转让
标题翻译： VERBINDUNG MIT SELBSTOPFERNDER GRUPPE
公开(公告)号：EP3156424A1
公开(公告)日：2017-04-19
申请号：EP15799360.1
申请日：2015-05-27
申请人： LegoChem Biosciences, Inc.
发明人： KIM, Yong Zu , PARK, Tae Kyo , WOO, Sung Ho , KIM, Sun Young , CHO, Jong Un , JUNG, Doo Hwan , YANG, Jeon , MIN, Ji Young , LEE, Hyang Sook , PARK, Yun Hee , RYU, Jeong Hee , OH, Kyu Man , OH, Yeong Soo , CHAE, Jeiwook , SONG, Ho Young , CHUNG, Chul-Woong
IPC分类号： C07K19/00 , C07D249/04
CPC分类号： A61K47/6871 , A61K47/549 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6813 , A61K47/6855 , A61K47/6889 , A61K47/69 , A61K2039/505 , C07D249/04 , C07D487/04 , C07D519/00 , C07K16/32 , C07K19/00 , C07K2317/24
摘要： Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
摘要翻译：本发明提供的是包含自褪色基团的化合物，并且根据本发明的包含自褪色基团的化合物可以包含具有底物特异性的蛋白质（例如，寡肽，多肽，抗体等）具有特定功能或活性的靶和活性剂（例如药物，毒素，配体，检测探针等）。

3. 发明公开

EP2997968A1 Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same 无效
标题翻译：艾森 - （III）-Hydroxidkomplexe mit aktivierten Glucosesirups und Verfahren zur Herstellung davon
公开(公告)号：EP2997968A1
公开(公告)日：2016-03-23
申请号：EP14386023.7
申请日：2014-09-22
申请人： Tseti, Ioulia
发明人： Tseti, Ioulia
IPC分类号： A61K31/295 , A61K31/7004
CPC分类号： A61K33/26 , A61K31/295 , A61K31/7004 , A61K47/69
摘要： The present invention generally relates to iron (III) carbohydrate complexes and to processes for the manufacture thereof. The product obtainable according to the method of the present invention may be safely used to the general population or animals in the therapy of iron deficiency. The process of the invention includes the steps of (i) providing an aqueous solution of glucose syrup having a certain dextrose equivalent (DE), (ii) adding one or more oxidizing bleaching agents, thereby obtaining the activated glucose syrup; (iii) converting said activated glucose syrup into a complex with iron (III) hydroxide; and (iv) obtaining a complex of iron (III) hydroxide and activated glucose syrup.
摘要翻译：本发明一般涉及铁（III）碳水化合物复合物及其制备方法。根据本发明的方法可获得的产品可以安全地用于一般人群或动物治疗铁缺乏症。本发明的方法包括以下步骤：（i）提供具有一定葡萄糖当量（DE）的葡萄糖浆水溶液，（ii）加入一种或多种氧化漂白剂，从而得到活化葡萄糖浆; （iii）将所述活化的葡萄糖浆与氢氧化铁（III）转化成络合物; 和（iv）获得氢氧化铁（III）和活化葡萄糖浆的络合物。

4. 发明公开

EP2872153A1 ACELLULAR PRO-TOLEROGENIC COMPOSITIONS AND PROCESS FOR MAKING SAME 有权
标题翻译：脱细胞PROTOLEROGENE成分和方法FOR THEIR
公开(公告)号：EP2872153A1
公开(公告)日：2015-05-20
申请号：EP13817560.9
申请日：2013-07-12
申请人： Canadian Blood Services
发明人： SCOTT, Mark D. , WANG, Duncheng , TOYOFUKU, Wendy M.
IPC分类号： A61K35/14 , A61K31/7105 , A61K47/30 , A61P37/02 , C12N5/078 , C12N5/0783
CPC分类号： A61K35/17 , A61K9/0019 , A61K35/00 , A61K35/14 , A61K39/0008 , A61K39/001 , A61K47/60 , A61K47/69 , A61K47/6901 , A61K2035/122 , A61K2035/124 , A61K2039/515 , A61K2039/577 , C12N5/0637 , C12N5/0638 , C12N15/113 , C12N2310/141 , C12N2500/50 , C12N2501/00 , C12N2501/65 , C12N2502/1114
摘要： This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.

5. 发明公开

EP2872151A1 ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT/PREVENTION OF AUTO-IMMUNE DISEASES 有权
标题翻译：对于自身免疫性疾病的治疗/预防脱细胞PRO-致耐受性的组合物
公开(公告)号：EP2872151A1
公开(公告)日：2015-05-20
申请号：EP13817292.9
申请日：2013-07-12
申请人： Canadian Blood Services
发明人： SCOTT, Mark D. , WANG, Duncheng , TOYOFUKU, Wendy M.
IPC分类号： A61K35/14 , A61K31/7105 , A61K47/30 , A61P37/02 , C12N5/078 , C12N5/0783
CPC分类号： A61K35/17 , A61K9/0019 , A61K35/00 , A61K35/14 , A61K39/0008 , A61K39/001 , A61K47/60 , A61K47/69 , A61K47/6901 , A61K2035/122 , A61K2035/124 , A61K2039/515 , A61K2039/577 , C12N5/0637 , C12N5/0638 , C12N15/113 , C12N2310/141 , C12N2500/50 , C12N2501/00 , C12N2501/65 , C12N2502/1114
摘要： This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.

6. 发明公开

EP2704715A4 TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+REGULATORY T CELLS 审中-公开
标题翻译：合成耐受性NANO支持生成CD8 + T细胞-REGULIERENDER
公开(公告)号：EP2704715A4
公开(公告)日：2015-03-04
申请号：EP12777648
申请日：2012-04-27
申请人： SELECTA BIOSCIENCES INC
发明人： KISHIMOTO TAKASHI KEI , FRASER CHRISTOPHER , MALDONADO ROBERTO A
IPC分类号： A61K31/445 , A61K9/14 , A61K9/16 , A61K39/38 , A61K39/395 , A61K47/30 , A61K47/48 , A61P29/00 , C12N5/0783
CPC分类号： A61K39/385 , A61K9/127 , A61K9/14 , A61K9/51 , A61K9/5115 , A61K9/5146 , A61K9/5153 , A61K31/192 , A61K38/13 , A61K38/1816 , A61K38/38 , A61K39/00 , A61K39/0008 , A61K39/001 , A61K39/35 , A61K39/36 , A61K47/50 , A61K47/52 , A61K47/544 , A61K47/593 , A61K47/643 , A61K47/69 , A61K47/6923 , A61K47/6929 , A61K47/6937 , A61K2039/5154 , A61K2039/55511 , A61K2039/55555 , A61K2039/577 , B82Y5/00 , B82Y40/00 , G01N33/505 , G01N33/56972 , G01N2333/7051 , G01N2333/70514 , G01N2333/70517 , A61K2300/00
摘要： Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.

7. 发明公开

EP2701739A4 TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES 有权
标题翻译：合成耐受性NANO支持FOR抗体反应的减少
公开(公告)号：EP2701739A4
公开(公告)日：2015-03-04
申请号：EP12777688
申请日：2012-04-27
申请人： SELECTA BIOSCIENCES INC
发明人： FRASER CHRISTOPHER , KISHIMOTO TAKASHI KEI , MALDONADO ROBERTO A
IPC分类号： A61K31/445 , A61K9/14 , A61K9/16 , A61K39/38 , A61K39/395 , A61K47/30 , A61K47/48 , A61P29/00
CPC分类号： A61K39/385 , A61K9/127 , A61K9/14 , A61K9/51 , A61K9/5115 , A61K9/5146 , A61K9/5153 , A61K31/192 , A61K38/13 , A61K38/1816 , A61K38/38 , A61K39/00 , A61K39/0008 , A61K39/001 , A61K39/35 , A61K39/36 , A61K47/50 , A61K47/52 , A61K47/544 , A61K47/593 , A61K47/643 , A61K47/69 , A61K47/6923 , A61K47/6929 , A61K47/6937 , A61K2039/5154 , A61K2039/55511 , A61K2039/55555 , A61K2039/577 , B82Y5/00 , B82Y40/00 , G01N33/505 , G01N33/56972 , G01N2333/7051 , G01N2333/70514 , G01N2333/70517 , A61K2300/00
摘要： Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.

8. 发明公开

EP2704750A4 TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS 有权转让
标题翻译：合成耐受性NANO支撑作用的效应T细胞特异性抗原缺失
公开(公告)号：EP2704750A4
公开(公告)日：2015-01-07
申请号：EP12777664
申请日：2012-04-27
申请人： SELECTA BIOSCIENCES INC
发明人： FRASER CHRISTOPHER , KISHIMOTO TAKASHI KEI , MALDONADO ROBERTO A
IPC分类号： A61K47/48 , A61K9/127 , A61K31/445 , A61K39/38 , A61K47/30
CPC分类号： A61K39/385 , A61K9/127 , A61K9/14 , A61K9/51 , A61K9/5115 , A61K9/5146 , A61K9/5153 , A61K31/192 , A61K38/13 , A61K38/1816 , A61K38/38 , A61K39/00 , A61K39/0008 , A61K39/001 , A61K39/35 , A61K39/36 , A61K47/50 , A61K47/52 , A61K47/544 , A61K47/593 , A61K47/643 , A61K47/69 , A61K47/6923 , A61K47/6929 , A61K47/6937 , A61K2039/5154 , A61K2039/55511 , A61K2039/55555 , A61K2039/577 , B82Y5/00 , B82Y40/00 , G01N33/505 , G01N33/56972 , G01N2333/7051 , G01N2333/70514 , G01N2333/70517 , A61K2300/00
摘要： Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to reduce antigen-specific activation of innate immune cells.

9. 发明公开

EP2704693A1 CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS 审中-公开
标题翻译： GESTEUERTE FREISETZUNG VON IMMUNSUPPRESSIVA AUS SYNTHETISCHENNANOTRÄGERN
公开(公告)号：EP2704693A1
公开(公告)日：2014-03-12
申请号：EP12776474.4
申请日：2012-04-27
申请人： Selecta Biosciences, Inc.
发明人： ALTREUTER, David, H. , GRISET, Aaron, P. , MALDONADO, Roberto, A.
IPC分类号： A61K9/16 , A61K47/48 , A61K9/14 , A61K47/30 , A61K31/445
CPC分类号： A61K39/385 , A61K9/127 , A61K9/14 , A61K9/51 , A61K9/5115 , A61K9/5146 , A61K9/5153 , A61K31/192 , A61K38/13 , A61K38/1816 , A61K38/38 , A61K39/00 , A61K39/0008 , A61K39/001 , A61K39/35 , A61K39/36 , A61K47/50 , A61K47/52 , A61K47/544 , A61K47/593 , A61K47/643 , A61K47/69 , A61K47/6923 , A61K47/6929 , A61K47/6937 , A61K2039/5154 , A61K2039/55511 , A61K2039/55555 , A61K2039/577 , B82Y5/00 , B82Y40/00 , G01N33/505 , G01N33/56972 , G01N2333/7051 , G01N2333/70514 , G01N2333/70517 , Y02A50/401 , Y02A50/41 , A61K2300/00
摘要： Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to reduce antigen-specific activation of innate immune cells.
摘要翻译：公开了合成纳米载体方法和相关组合物，其包括施用抗原和免疫抑制剂的B细胞和/或MHC II类限制性表位以减少先天免疫细胞的抗原特异性激活。

10. 发明公开

EP1773878A4 INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF 有权转让
标题翻译：胰岛素接头，其制剂和应用
公开(公告)号：EP1773878A4
公开(公告)日：2012-06-20
申请号：EP05773736
申请日：2005-07-19
申请人： BIOCON LTD
发明人： RADHAKRISHNAN BALASINGAM , AGGARWAL DITI , FERRO MICHELLE , JAMES KENNETH D , MALKAR NAVDEEP B , MILLER MARK A , PAVLIV LEO , POLOWY KAREN , PUSKAS KAREN , EKWURIBE NNOCHIRII N
IPC分类号： C07K14/62
CPC分类号： C07K14/62 , A61K9/0095 , A61K9/2013 , A61K9/2018 , A61K33/30 , A61K38/00 , A61K38/28 , A61K45/06 , A61K47/60 , A61K47/69 , A61K2300/00

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式